The role of PRMT1 in cellular regulation and disease: Insights into biochemical functions and emerging inhibitors for cancer therapy

IF 4.3 3区 医学 Q1 PHARMACOLOGY & PHARMACY European Journal of Pharmaceutical Sciences Pub Date : 2024-11-07 DOI:10.1016/j.ejps.2024.106958
Shiyao Ma , Shanhui Yi , Hui Zou , Shasha Fan , Yin Xiao
{"title":"The role of PRMT1 in cellular regulation and disease: Insights into biochemical functions and emerging inhibitors for cancer therapy","authors":"Shiyao Ma ,&nbsp;Shanhui Yi ,&nbsp;Hui Zou ,&nbsp;Shasha Fan ,&nbsp;Yin Xiao","doi":"10.1016/j.ejps.2024.106958","DOIUrl":null,"url":null,"abstract":"<div><div>Protein Arginine Methyltransferase 1 (PRMT1), a primary protein arginine methyltransferase, plays a pivotal role in cellular regulation, influencing processes such as gene expression, signal transduction, and cell differentiation. Dysregulation of PRMT1 has been linked to the development of various cancers, establishing it as a key target for therapeutic intervention. This review synthesizes the biochemical characteristics, structural domains, and functional mechanisms of PRMT1, focusing on its involvement in tumorigenesis. Additionally, the development and efficacy of emerging PRMT1 inhibitors as potential cancer therapies are examined. By employing molecular modeling and insights from existing literature, this review posits that targeting PRMT1’s methyltransferase activity could disrupt cancer progression, providing valuable insights for future drug development.</div></div>","PeriodicalId":12018,"journal":{"name":"European Journal of Pharmaceutical Sciences","volume":"204 ","pages":"Article 106958"},"PeriodicalIF":4.3000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0928098724002719","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Protein Arginine Methyltransferase 1 (PRMT1), a primary protein arginine methyltransferase, plays a pivotal role in cellular regulation, influencing processes such as gene expression, signal transduction, and cell differentiation. Dysregulation of PRMT1 has been linked to the development of various cancers, establishing it as a key target for therapeutic intervention. This review synthesizes the biochemical characteristics, structural domains, and functional mechanisms of PRMT1, focusing on its involvement in tumorigenesis. Additionally, the development and efficacy of emerging PRMT1 inhibitors as potential cancer therapies are examined. By employing molecular modeling and insights from existing literature, this review posits that targeting PRMT1’s methyltransferase activity could disrupt cancer progression, providing valuable insights for future drug development.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
PRMT1 在细胞调控和疾病中的作用:洞察生化功能和用于癌症治疗的新兴抑制剂。
蛋白精氨酸甲基转移酶 1(PRMT1)是一种初级蛋白精氨酸甲基转移酶,在细胞调控中发挥着关键作用,影响着基因表达、信号转导和细胞分化等过程。PRMT1 的失调与各种癌症的发生有关,因此成为治疗干预的关键靶点。本综述综述了 PRMT1 的生化特征、结构域和功能机制,重点介绍了它在肿瘤发生中的参与。此外,还研究了作为潜在癌症疗法的新兴 PRMT1 抑制剂的开发和疗效。通过利用分子建模和现有文献中的见解,本综述认为针对 PRMT1 的甲基转移酶活性可以破坏癌症的进展,为未来的药物开发提供有价值的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
9.60
自引率
2.20%
发文量
248
审稿时长
50 days
期刊介绍: The journal publishes research articles, review articles and scientific commentaries on all aspects of the pharmaceutical sciences with emphasis on conceptual novelty and scientific quality. The Editors welcome articles in this multidisciplinary field, with a focus on topics relevant for drug discovery and development. More specifically, the Journal publishes reports on medicinal chemistry, pharmacology, drug absorption and metabolism, pharmacokinetics and pharmacodynamics, pharmaceutical and biomedical analysis, drug delivery (including gene delivery), drug targeting, pharmaceutical technology, pharmaceutical biotechnology and clinical drug evaluation. The journal will typically not give priority to manuscripts focusing primarily on organic synthesis, natural products, adaptation of analytical approaches, or discussions pertaining to drug policy making. Scientific commentaries and review articles are generally by invitation only or by consent of the Editors. Proceedings of scientific meetings may be published as special issues or supplements to the Journal.
期刊最新文献
Automated Extrusion-Based Dispensing: Personalized Dosing and Quality Control of Clopidogrel Tablets for Pediatric Care. Multiphysics Simulation of Liposome Release from Hydrogels for Cavity Filling Following Patient-Specific Breast Tumor Surgery. Towards optimization of dexamethasone therapy in the maintenance phase of pediatric acute lymphoblastic leukemia: a population pharmacokinetic and pharmacodynamic study of dexamethasone and metabolite. Disassembly and in vitro cell compatibility of α-lactalbumin particulates under physiologically relevant conditions Exploration of solubilisation effects facilitated by the combination of Soluplus® with ionic surfactants.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1